Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Meropenem trihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Meropenem is an antibiotic used in adults and children aged 3 months and older. It works by killing bacteria that cause infections. It belongs to a group of medicines called carbapenem antibiotics. Meropenem is used to treat:
Meropenem
You must not be given Meropenem if: • •
you are allergic (hypersensitive) to meropenem or any of the other ingredients (listed in section 6). you are allergic (hypersensitive) to other antibiotics such as penicillins, cephalosporins, or carbapenems as you may also be allergic to meropenem.
Warnings and precautions Talk to your doctor, pharmacist or nurse before receiving Meropenem if:
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. It is preferable to avoid the use of Meropenem during pregnancy. Your doctor will decide whether you should use Meropenem. It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving Meropenem. Small amounts of this medicine may pass into the breast milk. Therefore, your doctor will decide whether you should use Meropenem while breast-feeding. Driving and using machines No studies on the effect on the ability to drive and use machines have been performed. Meropenem has been associated with headache and tingling or pricking skin (paraesthesia). Any of these side effects could affect your ability to drive or operate machines. Meropenem may cause involuntary muscle movements which may cause the person's body to shake rapidly and uncontrollably (convulsions). This is usually accompanied with a loss of consciousness. Do not drive or use machines if you experience this side effect. Meropenem contains sodium This medicinal product contains 290 mg sodium (main component of cooking/table salt) per bag, equivalent to 14.5 % of the recommended maximum daily dietary intake of sodium for an adult. If you have a condition which requires you to monitor your sodium intake, please inform your doctor or pharmacist.
3.
How Meropenem is given
Meropenem is usually given by a doctor or nurse as a drip (intravenous infusion) directly into a vein. The usual dose The correct dose of meropenem for you will be decided by your doctor and depends on the severity and type of infection, whether you are on any other antibiotics; your weight and age; how well your kidneys are working. Children and adolescents The dose for children over 3 months old and up to 12 years of age is decided using the age and weight of the child. The usual dose is between 10 mg (milligrams) and 40 mg of meropenem for each kilogram (kg) that the child weighs. A dose is usually given every 8 hours. Children who weigh over 50 kg will be given an adult dose. Adults The dose for adults is usually between 500 mg and 2000 mg. You will usually receive a dose every 8 hours. Patients with kidney problems If you have a kidney problem, your doctor may change your dose. Talk to your doctor if this applies to you.
Meropenem
4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Severe allergic reactions If you have any of these signs and symptoms, tell your doctor or nurse straight away. You may need urgent medical treatment. The signs and symptoms may include a sudden onset of:
Rare (may affect up to 1 in 1,000 people)
Meropenem
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bag. The expiry date refers to the last day of that month. Do not store above 30 °C. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed:
What Meropenem contains The active substance is meropenem. One two-chamber bag contains meropenem trihydrate equivalent to 1000 mg anhydrous meropenem. The other ingredients are sodium chloride, water for injections and sodium carbonate. What Meropenem looks like and contents of the pack
Meropenem is provided in colourless multilayer plastic two-chamber bags with a set-port. One side is opaque, the other side is transparent. Before reconstitution, Meropenem contains a white to light yellow powder in one chamber and 50 ml of a clear and colourless sodium chloride solution in the other chamber. After reconstitution, the chamber contains a clear and colourless solution for infusion. Meropenem is supplied as packs containing 24 two-chamber bags. Marketing Authorisation Holder
B. Braun Melsungen AG Carl-Braun-Straße 1 34212 Melsungen Germany Postal address: 34209 Melsungen Germany Phone: +49-5661-71-0 Fax: +49-5661-71-4567 Manufacturer ACS Dobfar S.p.A. Nucleo Industriale S. Atto 64100 Teramo (TE) ITALY
This leaflet was last revised in 06/2025
<—————————————————————————————————————————-The following information is intended for medical or healthcare professionals only:
Posology The tables below provide general recommendations for dosing. The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response. A dose of up to 2000 mg three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections. Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below). Adults and adolescents Infection Severe pneumonia including hospital and ventilator-associated pneumonia
Dose to be administered every 8 hours 500 mg or 1000 mg
Broncho-pulmonary infections in cystic fibrosis Complicated urinary tract infections Complicated intra-abdominal infections Intra- and post-partum infections Complicated skin and soft tissue infections Acute bacterial meningitis Management of febrile neutropenic patients
2000 mg 500 mg or 1000 mg 500 mg or 1000 mg 500 mg or 1000 mg 500 mg or 1000 mg 2000 mg 1000 mg
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes.
Renal impairment The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the administration of these dose adjustments for a unit dose of 2000 mg.
Creatinine clearance (ml/min)
Dose (based on "unit" dose range of 500 mg or 1000 mg or 2000 mg, see table above)
Frequency
26 – 50
one unit dose
10 – 25
half of one unit dose
every 12 hours
< 10
half of one unit dose
every 24 hours
every 12 hours
Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle. There are no established dose recommendations for patients receiving peritoneal dialysis. Hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. Dose in elderly patients No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
Paediatric population Children under 3 months of age The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen. Children from 3 months to 11 years of age and up to 50 kg body weight The recommended dose regimens are shown in the table below: Infection Severe pneumonia including hospital and ventilator-associated pneumonia Broncho-pulmonary infections in cystic fibrosis Complicated urinary tract infections Complicated intra-abdominal infections Complicated skin and soft tissue infections Acute bacterial meningitis
Dose to be administered every 8 hours 10 or 20 mg/kg 40 mg/kg 10 or 20 mg/kg 10 or 20 mg/kg 10 mg or 20 mg 40 mg/kg
Management of febrile neutropenic patients
20 mg/kg
Children over 50 kg body weight The adult dose should be administered. There is no experience in children with renal impairment. Method of administration Intravenous Infusion Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes. Incompatibilities In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Shelf life after reconstitution The reconstituted drug product is intended for single use only.
Chemical and physical in-use stability has been demonstrated for 3 hours at 25 °C or for 24 hours at 2 – 8 °C. From a microbiological point of view, unless the method of opening and reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.
Shelf life after first opening The opened two-chamber bag should be used immediately.
Special precautions for disposal and other handling Do not cover any portion of foil strip with patient label. Do not use in series connection. Discard unit if foil strip of container is damaged. Peel foil strip only when ready for use. Visually inspect medicinal product prior to reconstition. The solution should only be used if it is clear, colourless and practically free from particles. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Instructions for giving Meropenem to yourself or someone else at home Some patients, parents and careers are trained to give Meropenem at home. Warning – You should only give this medicine to yourself or someone else at home after a doctor or nurse has trained you. Instructions for reconstitution of the Meropenem two-chamber bag 1. Unlatch side tab and unfold container (fig. 1). 2. Peel foil strip from drug powder chamber (fig. 2). 3. Fold container just below solvent meniscus and squeeze until seal between solvent and powder pops open (fig. 3). 4. Shake the solvent-powder mixture until the drug powder is completely dissolved. 5. Visually inspect the reconstituted solution for particulate matter. Do not use unless the solution is clear, colourless and practically free from particles. 6. Squeeze folded container just below the solution meniscus to pop the second seal and release liquid into the port (fig. 4).
7. Remove foil tab cover from set port and attach sterile administration set (fig. 5). Hang bag on IV pole.
fig. 1
fig. 2
fig. 3
fig. 4
fig. 5
Meropenem 1000 mg powder and solvent for solution for infusion comes as infusion containing 1000mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Meropenem 1000 mg powder and solvent for solution for infusion is meropenem trihydrate.
This leaflet reproduces the patient information leaflet approved for Meropenem 1000 mg powder and solvent for solution for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Meropenem is indicated for the treatment of the following infections in adults and children aged 3 months and older (see sections 4.4 and 5.1).
• Severe pneumonia, including hospital and ventilator-associated pneumonia
• Broncho-pulmonary infections in cystic fibrosis
• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Intra- and post-partum infections
• Complicated skin and soft tissue infections
• Acute bacterial meningitis
Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Posology
The tables below provide general recommendations for dosing.
The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.
A dose of up to 2000 mg three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections.
Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).
Adults and adolescents
Infection
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia
500 mg or 1000 mg
Broncho-pulmonary infections in cystic fibrosis
2000 mg
Complicated urinary tract infections
500 mg or 1000 mg
Complicated intra-abdominal infections
500 mg or 1000 mg
Intra- and post-partum infections
500 mg or 1000 mg
Complicated skin and soft tissue infections
500 mg or 1000 mg
Acute bacterial meningitis
2000 mg
Management of febrile neutropenic patients
1000 mg
Renal impairment
The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the administration of these dose adjustments for a unit dose of 2000 mg.
Creatinine clearance (ml/min)
Dose
(based on “unit” dose range of 500 mg or 1000 mg or 2000 mg, see table above)
Frequency
26 - 50
one unit dose
every 12 hours
10 - 25
half of one unit dose
every 12 hours
< 10
half of one unit dose
every 24 hours
Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.
There are no established dose recommendations for patients receiving peritoneal dialysis.
Hepatic impairment
No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).
Dose in elderly patients
No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
Paediatric population
Children under 3 months of age
The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).
Children from 3 months to 11 years of age and up to 50 kg body weight
The recommended dose regimens are shown in the table below:
Infection
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia
10 or 20 mg/kg
Broncho-pulmonary infections in cystic fibrosis
40 mg/kg
Complicated urinary tract infections
10 or 20 mg/kg
Complicated intra-abdominal infections
10 or 20 mg/kg
Complicated skin and soft tissue infections
10 or 20 mg/kg
Acute bacterial meningitis
40 mg/kg
Management of febrile neutropenic patients
20 mg/kg
Children over 50 kg body weight
The adult dose should be administered.
There is no experience in children with renal impairment.
Method of administration
Intravenous Infusion
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Extended infusion (i.e. 0.5 - 2 g meropenem infused over 3 hours) may be used for less susceptible bacteria to achieve a higher target of T > MIC.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (penicillin's or cephalosporins).
The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.
Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. resistance
Resistance to penems of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.
Hypersensitivity reactions
As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).
Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.
If a severe allergic reaction occurs, the medicinal product should be discontinued, and appropriate measures taken.
Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalized exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see section 4.8). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.
Antibiotic-associated colitis
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8). Discontinuation of therapy with meropenem and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Seizures
Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).
Drug-induced liver injury (DILI)
Hepatic function should be closely monitored during treatment with meropenem due to the risk of DILI (see section 4.8). If severe DILI occurs, treatment discontinuation should be considered as clinically appropriate. Meropenem should be reintroduced only if assessed as essential for treatment.
Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).
Direct antiglobulin test (Coombs test) seroconversion
A positive direct or indirect Coombs test may develop during treatment with meropenem.
Concomitant use with valproic acid/sodium valproate/valpromide
The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5). Other antimicrobial agents should be considered as alternatives to carbapenem antibiotics. If administration of carbapenem is necessary, therapeutic drug monitoring of valproate concentration is warranted when a carbapenem-valproic acid combination therapy is applied, especially on initiating or stopping the carbapenem antibiotic.
Warnings/precautions regarding excipients
This medicinal product contains 290 mg sodium per bag, equivalent to 14.5 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.
No specific medicinal product interaction studies other than probenecid were conducted.
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Co-administration of meropenem with probenecid is not recommended.
Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60 – 100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).
Oral anti-coagulants
Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.
Paediatric population
Interaction studies have only been performed in adults.
Pregnancy
There are limited data from the use of meropenem in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.
Breast-feeding
Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.
Fertility
There are no data on the effects of meropenem on fertility in humans. Reproductive studies in animals have shown no effects on fertility.
No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.
Summary of the safety profile
In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3 %), rash (1.4 %), nausea/vomiting (1.4 %) and injection site inflammation (1.1 %). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6 %) and increased hepatic enzymes (1.5 – 4.3 %).
Tabulated risk of adverse reactions
In the table below all adverse reactions are listed by system organ class and frequency: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
System organ class
Frequency
Event
Infections and infestations
Uncommon
oral and vaginal candidiasis
Blood and lymphatic system disorders
Common
thrombocythaemia
Uncommon
eosinophilia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis, haemolytic anaemia
Immune system disorders
Uncommon
angioedema, anaphylaxis (see sections 4.3 and 4.4)
Metabolism and nutrition disorders
Uncommon
hypokalaemia
Psychiatric disorders
Rare
delirium
Nervous system disorders
Common
headache
Uncommon
paraesthesiae
Rare
convulsions (see section 4.4)
Gastrointestinal disorders
Common
diarrhoea, vomiting, nausea, abdominal pain increase
Uncommon
antibiotic-associated colitis (see section 4.4)
Hepatobiliary disorders
Common
transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased.
Uncommon
blood bilirubin increased, drug-induced liver injury 1
Skin and subcutaneous tissue disorders
Common
rash, pruritus
Uncommon
urticaria, toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme (see section 4.4)
Not known
drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (see section 4.4)
Renal and urinary disorders
Uncommon
blood creatinine increased, blood urea increased
General disorders and administration site conditions
Common
inflammation, pain
Uncommon
thrombophlebitis, pain at the injection site
1 DILI includes hepatitis and liver failure.
Paediatric population
Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.
In individuals with normal renal function, rapid renal elimination will occur.
Haemodialysis will remove meropenem and its metabolite.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Meropenem 1000 mg powder and solvent for solution for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.